关于为控股子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 近日，春天之星向中国光大银行股份有限公司青岛分行（以下简称"光大银行青岛分 行"）申请人民币5,000万元的授信业务，公司为本次授信业务提供4,000万元的连带责任 保证。 上述担保事项在预计的担保额度范围内，无需另行召开董事会及股东会审议。 本次提供担保前，公司为春天之星提供的担保余额为8,000万元，本次提供担保后担保 余额为8,000万元，剩余可用担保额度为14,720万元。 本次担保提供后，扣除尚在有效期内的担保余额（包括：公司为漱玉医药物流（山东） | 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-099 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 一、担保情况概述 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于 2025 年 1 月 21 日召开第 四届董事会第三次会议，于 2025 年 2 月 6 日召开 2025 年第一次临时股东大会，审 ...

Core Points - The company, Shuyupingmin, announced the approval of a proposal to sell repurchased shares during the fourth board meeting on November 18, 2025 [2] - The sale will involve a maximum of 2,988,788 shares, representing 0.74% of the company's total share capital [2] - The sale will be conducted through centralized bidding and will take place within six months starting from December 10, 2025, to June 9, 2026, excluding periods prohibited by regulations [2] Summary by Sections - **Announcement Details** - The company disclosed the decision to sell repurchased shares as per the usage agreement outlined in the repurchase report published on February 22, 2024 [2] - The sale price will be determined based on the secondary market price [2] - **Regulatory Compliance** - The sale will adhere to the regulations set forth by the China Securities Regulatory Commission and the Shenzhen Stock Exchange regarding the prohibition of sales [2]

Core Viewpoint - The company has approved a plan to sell repurchased shares, which aligns with its previously disclosed intentions regarding the use of repurchased shares [1] Group 1: Share Repurchase and Sale - The company will sell up to 2,988,788 repurchased shares, representing 0.74% of its total share capital [1] - The sale will be conducted through a centralized bidding process and will take place within six months from the announcement date, specifically from December 10, 2025, to June 9, 2026, excluding any periods prohibited by regulations [1] - The selling price of the repurchased shares will be determined based on the secondary market price [1]

Core Points - The company, Shuyupingmin (SZ 301017), announced a temporary board meeting on November 18, 2025, to discuss the proposal for selling repurchased shares from 2024 [1] - For the first half of 2025, the company's revenue composition was as follows: retail accounted for 87.34%, wholesale for 9.4%, promotional and display consulting services for 2.49%, and other businesses for 0.77% [1] - As of the report, Shuyupingmin's market capitalization stood at 6.1 billion yuan [1]

Core Viewpoint - The company has approved a proposal to sell repurchased shares, which aligns with the previously disclosed purpose in the repurchase report [1] Group 1: Share Repurchase and Sale - The company’s board has approved the sale of shares that were repurchased in 2024 [1] - The sale will be conducted through centralized bidding and will take place within six months from the announcement date, starting 15 trading days after the disclosure [1] - The total number of shares to be sold is not to exceed 2.9888 million shares, representing 0.74% of the company's total share capital [1]

Core Viewpoint - The company has approved a proposal to sell repurchased shares, which aligns with the previously disclosed purpose in the repurchase report [1] Group 1 - The board of directors has passed a resolution regarding the sale of shares repurchased in 2024 [1] - The company plans to sell up to 2.9888 million shares, representing 0.74% of the total share capital [1] - The sale will be conducted through centralized bidding and will take place within six months after the announcement, starting 15 trading days from the date of disclosure [1]

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-098 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 关于出售 2024 年已回购股份的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 漱玉平民大药房连锁股份有限公司（以下简称"公司"）于 2025 年 11 月 18 日召开第 四届董事会第十三次会议审议通过了《关于出售 2024 年已回购股份的议案》，根据公司于 2024 年 2 月 22 日披露的《回购报告书》之用途约定，同意公司以集中竞价方式出售已回购 股份,实施期限为自本公告披露之日起 15 个交易日后的 6 个月内（即 2025 年 12 月 10 日至 2026 年 6 月 9 日，根据中国证监会及深圳证券交易所相关规定禁止出售的期间除外），本次 拟出售回购股份不超过 2,988,788 股，占公司总股本的 0.74%，出售价格根据二级市场价格 确定。具体情况如下： 一、公司已回购股份基本情况 公司于 2024 年 2 ...

| 证券代码：301017 | 证券简称：漱玉平民 | 公告编号：2025-097 | | --- | --- | --- | | 债券代码：123172 | 债券简称：漱玉转债 | | 漱玉平民大药房连锁股份有限公司 第四届董事会第十三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、董事会会议召开情况 漱玉平民大药房连锁股份有限公司（以下简称"公司"）第四届董事会第十三次会议于 2025 年 11 月 18 日在公司会议室以现场结合通讯表决的方式召开。会议通知已于 2025 年 11 月 18 日以书面、电子邮件等方式送达各位董事，本次会议为紧急临时会议，根据《公司 章程》相关规定，董事长在本次会议上就紧急召开本次会议的情况进行了说明，公司全体 董事均同意豁免本次董事会会议的通知时限要求。会议应到董事 9 人，实到董事 9 人，其 中董事长李文杰先生，董事李强先生、杨策先生，独立董事赵振基先生、李文明先生、晏 莉女士以通讯表决方式出席。公司高级管理人员列席了本次会议。会议由公司董事长李文 杰先生主持，本次会议召开符合《中华人民共和国公司 ...

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.92% on November 18, with Yao Yigou leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance - Notable gainers included: - Ren Da Medical (603108) with a closing price of 15.97, up 2.90% and a trading volume of 278,200 shares, totaling 442 million yuan [1] - People's Tongtai (600829) with a closing price of 17.72, up 6.49% and a trading volume of 1,148,700 shares, totaling 1.902 billion yuan [1] - Major decliners included: - Yao Yigou (300937) with a closing price of 33.95, down 6.37% and a trading volume of 115,000 shares, totaling 396 million yuan [2] - Luhua Pharmaceutical (002788) with a closing price of 10.29, down 5.86% and a trading volume of 467,300 shares, totaling 489 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 706 million yuan from institutional investors, while retail investors contributed a net inflow of 705 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing while retail investors remained active [2] Individual Stock Capital Flow - Ren Da Medical (603108) had a net inflow of 49.2 million yuan from institutional investors, while retail investors saw a net outflow of 65.5 million yuan [3] - Yao Yigou (300937) experienced a significant net outflow of 560.4 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different stocks within the sector [3]

Summary of Key Points Core Viewpoint - The latest financing balance of the ChiNext market is 527.316 billion yuan, with a week-on-week increase of 1.685 billion yuan, indicating a positive trend in financing activities [1]. Financing Balance Overview - The total margin balance for ChiNext stocks is 529.163 billion yuan, with a daily increase of 1.7 billion yuan [1]. - Among the stocks, 456 have seen an increase in financing balance, with 36 stocks experiencing a growth of over 10% [1]. - The stock with the highest increase in financing balance is Zhongyi Technology, which saw an increase of 89.43% to 380 million yuan, and its stock price rose by 20.01% [1][3]. Stocks with Significant Financing Balance Increase - Notable stocks with significant increases in financing balance include: - Zhongyi Technology: 89.43% increase, closing price 62.74 yuan, 20.01% increase [3]. - Shuyupingmin: 82.78% increase, closing price 15.58 yuan, 6.48% decrease [3]. - Guolian Aquatic Products: 66.90% increase, closing price 4.22 yuan, 9.33% increase [3]. - The average increase for stocks with over 10% growth was 4.26%, with four stocks hitting the daily limit [1][3]. Stocks with Decreased Financing Balance - A total of 490 stocks experienced a decrease in financing balance, with 12 stocks seeing a decline of over 10% [4]. - The stock with the largest decrease is Jianglong Shipbuilding, with a 28.41% drop to 197 million yuan [4]. - Other notable declines include Rongqi Technology and Rongxin Culture, with decreases of 18.32% and 15.66%, respectively [4]. Capital Flow Insights - On November 17, 28 stocks with increased financing balance saw net inflows of main funds, with the highest inflows in Xingyuan Material, Xuanya International, and Henggong Precision [2]. - Conversely, eight stocks experienced net outflows, with Haike Xinyuan and Minsheng Health seeing the largest outflows [2].